49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
September 2026 in “Clinical Cosmetic and Investigational Dermatology” In this case report, a 2-year-old girl with severe alopecia areata experienced significant hair regrowth after 37 weeks of treatment with dupilumab and minoxidil, but the combination of treatments and possible spontaneous recovery mean the improvement cannot be solely credited to dupilumab.
September 2026 in “DOAJ (DOAJ: Directory of Open Access Journals)” This study describes a case where a 2-year-old girl with severe alopecia areata showed marked hair regrowth after 37 weeks of treatment with dupilumab and minoxidil, but due to concurrent therapies and potential spontaneous recovery, improvements cannot solely be attributed to dupilumab.
In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.